



Eurofins Pharma Services

Eurofins Medigenomix GmbH – Professional Partner
in Pharmacogenetics and Pharmacogenomics

New Service: Detection of DNA and RNA in Bio-Pharmaceuticals (*residual DNA testing*)




Eurofins Medigenomix GmbH is adding a new service to its extensive DNA analysis portfolio: the detection of DNA and RNA in bio-pharmaceutical and biotechnological products.

With the increasing importance of protein based diagnostics and

therapeutics, *residual DNA testing* is gaining more and more weight.

Our service comprises the development and validation of new assays as well as the application of existing ones. Depending on the project and its demands applications are used which are based on PCR and/ or hybridisation methods such as direct PCR, qPCR, melting curve analysis und direct sequencing.



Aims of the analysis are typically:

- Monitoring of the production of e.g. antibodies to detect detrimental contaminations of the production cells with viruses
- Optimisation of production and purification processes (upstream / downstream processing) for e.g. protein-based diagnostic and therapeutic agents
- Batch release according to the requirements of regulatory authorities like the European Medicine Agency (EMA)

All analyses are carried out by our ISO 17025:2005 accredited laboratory.

Please contact us to discuss your project or your study in detail:
pharmacogenetics@medigenomix.de